Truist Securities Reiterates Hold on Globus Medical, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter has reiterated a 'Hold' rating on Globus Medical (NYSE:GMED) and maintained a price target of $65.
September 05, 2023 | 2:21 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Globus Medical's stock rating has been reiterated as 'Hold' by Truist Securities with a maintained price target of $65.
The reiteration of the 'Hold' rating and maintained price target by Truist Securities indicates that the analyst believes the stock is fairly valued at its current price. This could potentially lead to a neutral short-term impact on the stock price as it suggests that the stock is neither undervalued nor overvalued.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100